Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide cocktail vaccine study in recurrent or progressive malignant glioma
jRCTs031180148Phase 2Completed
- Start
- Mar 2014
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of URLC10, DEPDC1-9-294, FOXM1 peptide, kif20a peptide vaccine and VEGFR1 peptide vaccine in malignant glioma. Primary endpoints: Safety and Effectiveness. Started Mar 2014; status: completed.
02
Drugs
URLC10DEPDC1-9-294FOXM1 peptidekif20a peptide vaccineVEGFR1 peptide vaccine
03
Conditions
malignant glioma
Beyond the preview
Go deeper on jRCTs031180148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180148.